In patients already receiving incretin-based therapy for diabetes/obesity who still have NITs suggesting persistent F2–F3 disease, what clinical signals or NIT patterns lead you to prioritize (1) optimizing anti-obesity incretin dosing, (2) switching incretin class, or (3) adding a thyroid hormone receptor-β agonist for MASH?